Relay Therapeutics, Inc. reported Phase 1/2 trial data for zovegalisib, showing median progression-free survival of 11.1 months in patients with a specific type of breast cancer, as of March 16, 2026. The treatment was generally well-tolerated by 60 patients, with a 43% objective response rate among evaluable participants.